Want to see IN:SHK full AI Analyst Report?
SHK Stock Chart & Stats
₹140.10
₹7.61(5.41%)
At close: 4:00 PM EDT
₹140.10
₹7.61(5.41%)
Day’s Range― - ―
52-Week Range₹111.70 - ₹275.20
Previous CloseN/A
Volume897.53K
Average Volume (3M)19.27K
Market Cap
₹22.78B
Enterprise Value₹25.15K
Total Cash (Recent Filing)₹645.90M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)25.6
Beta1.73
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.21%
Share Statistics
EPS (TTM)6.43
Shares Outstanding138,420,800
10 Day Avg. Volume25,737
30 Day Avg. Volume19,269
Financial Highlights & Ratios
PEG Ratio-3.85
Price to Book (P/B)1.14
Price to Sales (P/S)0.66
P/FCF Ratio293.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.4
Revenue Forecast (FY)₹26.59B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line expansion over the 2021–2026 period indicates durable demand across fragrances and flavours. For a B2B specialty-chemicals supplier, steady revenue supports scale benefits, persistent customer engagement, and a base for margin recovery if cost or mix issues are addressed.
B2B Formulation & Manufacturing ModelA solutions-oriented B2B model with formulation, application support, and manufacturing creates sticky customer relationships and higher switching costs. Tailored blends and technical support favor repeat orders and new-product adoption, sustaining long-term revenue visibility.
Serviceable Balance Sheet And Expanded EquityModerate leverage combined with an expanding equity base provides capacity to fund operations and invest in manufacturing or R&D. While debt has increased, the overall balance-sheet scale and equity cushion support resilience through cycles and flexibility for strategic spending.
Bears Say
Sharp Margin CompressionA dramatic drop in gross and operating margins materially reduces intrinsic earnings power. Sustained margin compression limits cash available for reinvestment, R&D, or deleveraging, and undermines the ability to translate revenue growth into durable profit expansion.
Volatile And Weak Free Cash Flow ConversionInconsistent free cash flow and very poor conversion of earnings into cash restrict the company’s ability to fund capex, pay consistent dividends, or reduce leverage. Persistent working-capital or investment demands raise structural funding risk over 2–6 months and beyond.
Rising Debt With Declining ROEIncreasing leverage while ROE collapses signals the company is generating lower returns on a larger capital base. This combination erodes financial flexibility, raises interest-service vulnerability, and makes it harder to justify additional investment without clear profitability fixes.
S H Kelkar and Company Ltd News
SHK FAQ
What was S H Kelkar and Company Ltd’s price range in the past 12 months?
S H Kelkar and Company Ltd lowest stock price was ₹111.70 and its highest was ₹275.20 in the past 12 months.
What is S H Kelkar and Company Ltd’s market cap?
S H Kelkar and Company Ltd’s market cap is ₹22.78B.
When is S H Kelkar and Company Ltd’s upcoming earnings report date?
S H Kelkar and Company Ltd’s upcoming earnings report date is Nov 14, 2026 which is in 104 days.
How were S H Kelkar and Company Ltd’s earnings last quarter?
S H Kelkar and Company Ltd released its earnings results on Jul 28, 2026. The company reported ₹1.8 earnings per share for the quarter, beating the consensus estimate of ₹1 by ₹0.8.
Is S H Kelkar and Company Ltd overvalued?
According to Wall Street analysts S H Kelkar and Company Ltd’s price is currently Overvalued.
Does S H Kelkar and Company Ltd pay dividends?
S H Kelkar and Company Ltd pays a Semiannually dividend of ₹1 which represents an annual dividend yield of 1.21%. See more information on S H Kelkar and Company Ltd dividends here
What is S H Kelkar and Company Ltd’s EPS estimate?
S H Kelkar and Company Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does S H Kelkar and Company Ltd have?
S H Kelkar and Company Ltd has 138,420,800 shares outstanding.
What happened to S H Kelkar and Company Ltd’s price movement after its last earnings report?
S H Kelkar and Company Ltd reported an EPS of ₹1.8 in its last earnings report, beating expectations of ₹1. Following the earnings report the stock price went down -2.869%.
Which hedge fund is a major shareholder of S H Kelkar and Company Ltd?
Currently, no hedge funds are holding shares in IN:SHK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
S H Kelkar and Company Ltd
S H Kelkar and Company Limited, in conjunction with its subsidiary entities, functions as a principal producer and purveyor of aromatic compounds, flavorings, and various aroma ingredients, serving markets primarily in India and through exports. The company's fragrance offerings are incorporated into a broad spectrum of products, including those for personal hygiene, hair care, skin treatment, cosmetics, fabric conditioning, general household use, and high-end perfumes. Concurrently, its flavors are vital components in items such as dairy products, beverages, confectionery, baked goods, pharmaceuticals, nutraceuticals, and savory dishes. S H Kelkar markets its product lines through distinct brands like SHK, Cobra, and Keva, catering to a diverse customer base that spans major domestic and international Fast-Moving Consumer Goods (FMCG) corporations, alongside specialized blenders and manufacturers within the fragrance and flavor industries. The firm, established in 1914, is headquartered in Mumbai, India.
Technical Analysis
AVT Natural Products Limited
―
Camlin Fine Sciences Limited
―
Oriental Aromatics Ltd.
―
Privi Speciality Chemicals Limited
―
Rossari Biotech Ltd
―